Maury Raycroft
Stock Analyst at Jefferies
(0.62)
# 3,753
Out of 4,711 analysts
52
Total ratings
18.42%
Success rate
-18.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $3.35 | +108.96% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $2.54 | +136.22% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $2.99 | +468.56% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $3.10 | +512.90% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $2.90 | +417.24% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $23.80 | +63.87% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $1.01 | +494.06% | 1 | Mar 13, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Upgrades: Buy | $4 → $46 | $13.00 | +253.85% | 1 | Mar 6, 2024 | |
| MGX Metagenomi | Initiates: Buy | $23 | $4.05 | +467.90% | 1 | Mar 5, 2024 | |
| TPST Tempest Therapeutics | Initiates: Buy | $15 | $0.71 | +2,007.93% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.57 | +45.31% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $1.20 | +650.00% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.38 | +479.71% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $42.60 | -85.92% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $19.45 | +285.60% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $245.44 | -5.48% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.39 | +150.57% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $14.00 | +92.86% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.59 | +214.47% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.46 | +285.23% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $3.99 | +802.26% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.16 | +2,424.04% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $40.72 | +322.40% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.99 | +602.34% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.22 | +2,017.12% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $1.19 | +3,261.34% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $6.38 | +3,505.02% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $12.18 | +244.83% | 3 | Nov 1, 2017 |
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $3.35
Upside: +108.96%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.54
Upside: +136.22%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $2.99
Upside: +468.56%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $3.10
Upside: +512.90%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $2.90
Upside: +417.24%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $23.80
Upside: +63.87%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.01
Upside: +494.06%
Corbus Pharmaceuticals Holdings
Mar 6, 2024
Upgrades: Buy
Price Target: $4 → $46
Current: $13.00
Upside: +253.85%
Metagenomi
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $4.05
Upside: +467.90%
Tempest Therapeutics
Feb 8, 2024
Initiates: Buy
Price Target: $15
Current: $0.71
Upside: +2,007.93%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.57
Upside: +45.31%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $1.20
Upside: +650.00%
Jan 31, 2023
Initiates: Buy
Price Target: $8
Current: $1.38
Upside: +479.71%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $42.60
Upside: -85.92%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $19.45
Upside: +285.60%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $245.44
Upside: -5.48%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.39
Upside: +150.57%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $14.00
Upside: +92.86%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.59
Upside: +214.47%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $12.46
Upside: +285.23%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $3.99
Upside: +802.26%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.16
Upside: +2,424.04%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $40.72
Upside: +322.40%
Mar 31, 2021
Initiates: Buy
Price Target: $21
Current: $2.99
Upside: +602.34%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.22
Upside: +2,017.12%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $1.19
Upside: +3,261.34%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $6.38
Upside: +3,505.02%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $12.18
Upside: +244.83%